Cost-effectiveness study on influenza prevention in Hong Kong

Health Policy. 2001 Jun;56(3):215-34. doi: 10.1016/s0168-8510(00)00140-8.

Abstract

Introduction: Recent studies confirm that influenza vaccination confers health benefits and reduces direct and indirect costs associated with the illness. However, these studies did not examine the situation in southern China, a hypothetical influenza epicentre for the emergence of pandemic influenza viruses.

Methods: Surveillance data were collected in Hong Kong in 1993/94 and used economic model was used to estimate the medical and social costs associated with influenza-like illness (ILI) and to predict the cost-effectiveness of implementing an influenza prevention programme.

Findings: The estimated ILI incidence was 110/1000. It was highest in those between 1 and 25 years of age while the rate of hospitalization was highest in the elderly. Influenza occurred throughout the study period, which was a mild influenza year. The model predicted more than 660000 ILI cases in a non-epidemic year, in which influenza B virus predominated, with an average ILI-associated cost of HK$283/case (US$36) and vaccination-associated costs of HK$74 (US$9.50) per vaccinated individual.

Conclusion: The medical, social and monetary costs of ILI in Hong Kong were not observed to be large when compared with those in more developed countries where there is a clearly defined influenza season and recognized disease burden. From the perspective of a susceptible individual, the vaccine was cost-effective but from the perspective of society it was not, even with the most cost-effective strategy of targeting the elderly. However, if the vaccine were effective in controlling newly emerging and highly virulent strains, targeted vaccination programmes might be highly cost-effective.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Child, Preschool
  • Cost of Illness*
  • Cost-Benefit Analysis
  • Health Care Costs / classification*
  • Health Care Costs / statistics & numerical data
  • Health Services Research
  • Hong Kong / epidemiology
  • Humans
  • Immunization Programs / economics*
  • Infant
  • Influenza Vaccines / administration & dosage*
  • Influenza Vaccines / economics
  • Influenza, Human / economics*
  • Influenza, Human / epidemiology
  • Influenza, Human / prevention & control*
  • Population Surveillance

Substances

  • Influenza Vaccines